Results 1 to 10 of about 12,198 (151)

PCSK9 Inhibitors: The Evolving Future [PDF]

Health Science Reports
Introduction PCSK9 inhibitors are a novel class of medications that lower LDL cholesterol (LDL‐C) by increasing LDL receptor activity, promoting clearance of LDL‐C from the bloodstream.
Bijay Mukesh Jeswani, Shubhangi Sharma, Sawai Singh Rathore, Abubakar Nazir, Rohit Bhatheja, Kapil Kapoor   +5 more
doaj   +5 more sources

PCSK9 inhibitors

Swiss Medical Weekly, 2015
The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces LDL receptor recycling, leading to a decrease of low-density lipoprotein cholesterol (LDL-
Baris Gencer, Gilles Lambert, François Mach   +2 more
doaj   +8 more sources

Safety of PCSK9 inhibitors

Biomedicine and Pharmacotherapy, 2022
annually in Europe, 4 million people die from cardiovascular diseases, the main cause of which is atherosclerosis. In order to slow down the development of atherosclerotic plaques, the main therapeutic goal is to lower LDL cholesterol (LDL-C) level. Undoubtedly, statins are the basis of lipid-lowering therapy for many years.
Grzegorz Grzesk, Łukasz Wołowiec, Anna Labejszo   +2 more
exaly   +3 more sources

A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022

Frontiers in Endocrinology, 2023
BackgroundSince the approval of the proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies for marketing in 2015, PCSK9 inhibitors have attracted significant interest in the field of cardiovascular endocrinology.
Qin Luo, Qin Luo, Zhenchu Tang, Zhenchu Tang, Panyun Wu, Panyun Wu, Zhangling Chen, Zhangling Chen, Zhenfei Fang, Zhenfei Fang, Fei Luo, Fei Luo   +11 more
doaj   +3 more sources

Inadequate Response to PCSK9 Inhibitors. [PDF]

JACC Case Rep
Suboptimal response to various proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapies has been reported in the literature; however, inadequate response to proprotein convertase subtilisin/kexin type 9 monoclonal antibodies and small interference RNA is rare to our knowledge.A 68-year-old woman with hypercholesterolemia (baseline low-
Bimal T, Ayyalu T, Safarova MS, Donahoe S, Davila C, Dayspring T, Shapiro M, Gianos E.   +7 more
europepmc   +3 more sources

Do PCSK9 Inhibitors Impair Memory? A Dual Approach Combining Real-World Data and Genetic Evidence [PDF]

Pharmacy
Emerging evidence suggested a potential link between lipid-lowering therapies and neurocognitive effects, raising concerns regarding the possible adverse impact of PCSK9 inhibitors on memory loss.
Xuezhong Shi, Shijia Wang, Yongli Yang, Xudong Xia, Jingwen Fan, Jingjing Wang, Nana Wang, Xiaocan Jia   +7 more
doaj   +2 more sources

Integrating pharmacovigilance signals with real-world validation: a study on neurological events associated with PCSK9 inhibitors [PDF]

Frontiers in Medicine
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel drugs widely used in clinical practice for the treatment of dyslipidemia.
Bing Zhu, Qiqi Shao, Jun Cui, Zhenyan Fu, Yitong Ma   +4 more
doaj   +2 more sources

Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors represent a promising class of lipid‐lowering therapy, although their use has been limited by cost concerns.
Elias J. Dayoub, Lauren A. Eberly, Ashwin S. Nathan, Sameed Ahmed M. Khatana, Srinath Adusumalli, Ann Marie Navar, Jay Giri, Peter W. Groeneveld   +7 more
doaj   +3 more sources

Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis [PDF]

International Journal of Cardiology. Cardiovascular Risk and Prevention
Background: Peripheral artery disease (PAD) reflects systemic atherosclerosis driven by dyslipidemia, particularly elevated LDL-C. Despite first-line statin therapy, many patients fail to reach lipid targets or are intolerant, necessitating alternatives.
Khadeeja Ali Hamzah, Yousif Hameed Kurmasha, Mohamed Fouad Abdrabo, Mohamed F. Srour, Ali Saad Al-Shammari, Mohammed Hamed Ibrahium Badi, Mohammedsadeq A. Shweliya, Nihar Jena, Yasar Sattar   +8 more
doaj   +2 more sources

PCSK9 Inhibitors [PDF]

Cell, 2016
Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative
Pradeep, Natarajan, Sekar, Kathiresan
  +6 more sources